Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients

Table 3

Report on all papers about axitinib and stomatitis.

	Authors	Year	Neoplasia	Number of cases	Stomatitis number	Stomatitis; grade 1	Stomatitis grade 2	Stomatitis grade 3	Stomatitis grade 4
(1)	Rugo et al. [58]	2005	Phase I study; Advanced solid tumors; A: AG-013736; Axitinib 5–30 mg in 28-day cycle	A: 36	A: 4 (11%)	A: 2 (6%)		A: 2 (6%)
(2)	Ueda et al. [56]	2013	Metastatic renal cell carcinoma; A: axitinib; B: sorafenib	A: 359; B: 355	A: 54 (15.04%); B: 44 (12.39%)	A: 49 (13.64%); B: 43 (12.11%)		A: 5 (1.39%); B: 1 (0.28%)
(3)	Karam et al. [59]	2014	Phase II trial of locally advanced nonmetastatic clear cell renal carcinoma; A: axitinib 5 mg for up to 12 weeks	A: 24	A: 17 (70.8%)	A: 16 (67%)		A: 1 (4.2%)
(4)	Oh et al. [60]	2015	Phase I study: previously untreated advanced gastric cancer; A: axitinib 5 mg twice a day (days 1 to 21) with cisplatin 80 mg/m^2 (day 1) and capecitabine 1,000 mg/m^2 twice a day (days 1 to 14) in 21-day cycles	A: 22	A: 16 (72.7%)	A: 12 (54.5%)		A: 4 (18.2%)
	Total			441	91 (20.63%)	79 (17.91%)		12 (2.72%)